E Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$842K Buy
73,085
+61,594
+536% +$858K 0.02% 209
2026
Q2
$172K Sell
11,491
-2,665
-19% -$37K ﹤0.01% 460
2026
Q1
$207K Buy
+14,156
New +$226K 0.01% 447

Other funds holding CRVS

E Fund Management's CRVS Position: Q3 2026 in Review

E Fund Management increased its Corvus Pharmaceuticals (CRVS) stake by 536% in Q3 2026, buying an estimated $858K and bringing the position to 73,085 shares worth $842K. The position accounts for 0.02% of the portfolio, ranked #209.

E Fund Management first reported a position in CRVS in Q1 2026 and has held it in 3 quarters since. 177 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • E Fund Management held 73,085 shares of Corvus Pharmaceuticals worth $842K as of Q3 2026.
  • E Fund Management bought 61,594 Corvus Pharmaceuticals shares in Q3 2026, an estimated $858K.
  • Corvus Pharmaceuticals made up 0.02% of E Fund Management's portfolio in Q3 2026, its #209 holding.
  • E Fund Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 177 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on E Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.